Overview

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2033-09-30

Target enrollment:

Participant gender:

Summary

This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with B-ALL.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Amgen

Treatments:

blinatumomab